Zilucoplan: Side Effects
Known side effects, contraindications, and interactions
📌TL;DR
- •4 known side effects documented
- •3 mild, 0 moderate, 1 severe
- •3 contraindications listed
Compare side effects across multiple peptides →
Side Effects Severity Chart
Most common adverse events, including bruising (16%), erythema, and pain at the injection site. Generally mild (grade 1-2) and do not require treatment discontinuation. Site rotation recommended.
Reported in approximately 10% of patients in the RAISE trial. Generally mild and self-limiting. Not considered to be directly related to complement inhibition mechanism.
Reported in approximately 10% of patients. Usually mild and transient.
Boxed warning: C5 complement inhibition increases susceptibility to Neisseria meningitidis infections. Life-threatening and fatal cases have occurred with complement inhibitors. Risk persists even in vaccinated patients. Meningococcal vaccination required before treatment.
⛔Contraindications
- •Patients with unresolved serious Neisseria meningitidis infection
- •Patients not vaccinated against meningococcal bacteria (serogroups A, C, W, Y, and B) unless the risks of delaying treatment outweigh infection risk
- •Known hypersensitivity to zilucoplan or any excipient
⚠️Drug Interactions
- •No clinically significant drug-drug interactions identified. Zilucoplan has been used concomitantly with cholinesterase inhibitors, corticosteroids, and non-steroidal immunosuppressants in clinical trials without safety concerns.
Community-Reported Side Effects
See which side effects community members report most frequently.
Based on 50+ community reports
View community protocolsSafety Overview#
Zilucoplan has been evaluated for safety in the phase 3 RAISE trial (174 patients, 12 weeks), the ongoing RAISE-XT open-label extension (200 patients, median 1.2 years), and additional phase 2 studies. The overall safety profile is characterized by mild injection site reactions as the most common adverse event and a class-related risk of serious meningococcal infection managed through mandatory vaccination and a REMS program.
Boxed Warning: Meningococcal Infections#
The most important safety consideration for zilucoplan is the increased risk of serious meningococcal infections, a class effect of all complement inhibitors:
- Mechanism: C5 inhibition impairs the membrane attack complex (MAC), which is critical for immune defense against Neisseria meningitidis
- Risk: Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors
- Vaccination: Meningococcal vaccination (serogroups A, C, W, Y, and B) is required at least 2 weeks before initiating zilucoplan
- Limitations of vaccination: Meningococcal infections have occurred in vaccinated patients, so clinical vigilance remains necessary
- REMS program: Zilucoplan is available only through the ZILBRYSQ REMS, which ensures prescribers and patients are educated about the meningococcal infection risk
- Patient monitoring: Patients should be counseled to seek immediate medical attention for fever, headache with stiff neck, sensitivity to light, nausea/vomiting, or rash with dark purple spots
Injection Site Reactions#
Injection site reactions are the most frequently reported adverse event:
- Bruising: 16% of zilucoplan patients vs 9% placebo in RAISE
- Other ISRs: Erythema, pain, and swelling at the injection site
- Severity: Generally mild (grade 1-2)
- Management: Site rotation; no treatment discontinuation required in most cases
- Long-term trend: No worsening with continued daily injection in RAISE-XT
Other Common Adverse Events#
| Adverse Event | Zilucoplan (RAISE) | Placebo (RAISE) | Notes |
|---|---|---|---|
| Any TEAE | 77% | 70% | Slight excess over placebo |
| Injection-site bruising | 16% | 9% | Most common TEAE |
| Upper respiratory tract infection | ~10% | Similar | Not clearly drug-related |
| Diarrhea | ~10% | Similar | Usually mild, transient |
| Serious TEAEs | Similar | Similar | No excess with zilucoplan |
| Serious infections | Similar | Similar | No excess with zilucoplan |
Long-Term Safety (RAISE-XT)#
In the ongoing RAISE-XT extension with median exposure of 1.2 years:
- 94% of patients experienced at least one TEAE
- Most common long-term TEAEs: MG worsening (26%), COVID-19 (25%)
- Favorable long-term safety profile with good tolerability
- No new safety signals compared to the 12-week RAISE trial
Contraindications#
- Unresolved serious Neisseria meningitidis infection: Active meningococcal infection is an absolute contraindication
- Unvaccinated patients: Meningococcal vaccination required unless treatment urgency outweighs risk
- Hypersensitivity: Known allergy to zilucoplan or excipients
Drug Interactions#
No clinically significant drug-drug interactions have been identified. In clinical trials, zilucoplan was used safely with:
- Cholinesterase inhibitors (pyridostigmine)
- Corticosteroids (prednisone, prednisolone)
- Non-steroidal immunosuppressants (azathioprine, mycophenolate mofetil)
Related Reading#
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Zilucoplan
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.